Introduction {#s1}
============

Tirofiban, a short-acting non-peptide inhibitor of the glycoprotein (GP) IIb/IIIa receptor with high selectivity, can reversibly prevent platelet aggregation, and thrombi formation which play an important role in improving revascularization and clinical outcomes in acute ischemic stroke (AIS) patients ([@B1], [@B2]). Tirofiban combined with intravenous thrombolysis (IVT) was reported to be safe and effective in AIS patients ([@B3]--[@B5]). Recently, mechanical thrombectomy (MT) with second-generation devices has been recommended by AHA/ASA guidelines for AIS patients with intracranial large artery occlusion ([@B6], [@B7]). However, thrombectomy procedures can frequently lead to endothelial damage and subsequent platelets activation which may cause early reocclusion and clinical deterioration ([@B8]). In order to improve clinical outcomes, tirofiban has already been widely used in clinical practice in AIS patients treated with MT, even though the indication for AIS is not yet approved by US Food and Drug Administration. There were only four studies evaluated the feasibility of tirofiban combined with MT in AIS patients and results were not consistent ([@B9]--[@B12]). Whether the pharmacological advantage of tirofiban can evolve into satisfactory clinical outcomes remains under debate. Besides, previous trial which assessed clinical outcomes following IVT by stroke etiologies showed that when compared with patients with large artery atherosclerosis (LAA) stroke, those with cardioembolism (CE) stroke had worse clinical outcomes at 3-month follow-up ([@B13]). We assume such discrepancy also exists in stroke patients treated with MT. Based on this hypothesis, we conducted this study to examine the safety and efficacy of tirofiban combined with MT in LAA and CE patients.

Methods {#s2}
=======

Patients
--------

This was a prospective study conducted in three stroke units in China (Nanjing First Hospital, People\'s Hospital of Hunan Province and Changsha Central Hospital). The study protocol was approved by the Ethics Committee at the local hospital. Written informed consent was obtained before enrollment. We analyzed clinical and radiological data for all consecutive patients with AIS who underwent MT from January 2014 to December 2018. Patients were considered eligible for MT if they met the following criteria: (1) had a primary diagnosis of AIS; (2) age ≥ 18 years; (3) onset of acute neurological symptoms \<6 h; (4) intracranial large artery occlusion; (5) had a prestroke modified Rankin Scale (mRS) score of 0--2; (6) National Institutes of Health Stroke Scale (NIHSS) score ≥ 5 on admission. Exclusion criteria were: (1) history of intracranial hemorrhage before thrombectomy; (2) history of active bleeding or major surgery within 30 days; (3) platelet count \<100 × 10^9^/L; (4) blood glucose concentration \<2.8 mmol/L or \>22.0 mmol/L; (5) severe hepatic or renal dysfunction. Arterial occlusion site was assessed by computed tomographic angiography (CTA), magnetic resonance angiography (MRA), or digital subtraction angiography (DSA). The stroke etiology were classified according to the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) criteria: LAA, CE, and stroke of other determined or undetermined cause. Definitions of LAA and CE are shown in [Supplementary File](#SM1){ref-type="supplementary-material"}.

Interventions
-------------

According to current guidelines for AIS, intravenous recombinant tissue plasminogen activator (rtPA) was administered in some of the enrolled patients evaluated within 4.5 h of symptom onset ([@B6]). The intravenous rtPA dosage was 0.9 mg/kg to a maximum of 90 mg. For those who had received intravenous rtPA therapy, cranial Computed Tomography (CT) imaging was conducted prior to MT to exclude hemorrhage transformation. After CT imaging confirming the absence of intracranial hemorrhage, MT procedures were performed immediately in the cooperation of the neurointerventionalist and stroke neurologist/physician. Direct MT without intravenous rtPA was performed in patients with heavy thrombus burdens (i.e., NIHSS score ≥ 20 on admission or thrombus length exceeds 8 mm). All patients treated with MT using a second-generation stent retriever device (i.e., Solitaire FR and Trevo). DSA was conducted to evaluate vascular condition after thrombectomy. After completion of MT, follow-up brain CT were performed immediately and 12--24 h later. The use of tirofban or not was at the judgment of neurointerventional specialists. Of the 195 enrolled patients, 71 were treated with tirofiban. Tirofiban was administrated intra-arterially if (1) the target artery remained occluded after thrombectomy (35 out of 71); (2) reocclusion of the recanalized artery (27 out of 71); (3) residual stenosis ≥ 50% in occlusion site after thrombectomy (5 out of 71); (4) multiple attempts with retriever during thrombectomy (≥ 3 times) (4 out of 71). Depending on the thrombus burden, a low-dose bolus of tirofiban was injected at a rate of 1 ml/minute (dose ranged from 0.25 to 0.5 mg). Bridging dual antiplatelet therapy (aspirin 100 mg and clopidogrel 75 mg) were given 4 h before the cease of tirofiban treatment. Patients in control group only received antiplatelet agent (aspirin 100 mg or clopidogrel 75 mg) after the completion of thrombectomy.

Outcomes
--------

The main safety endpoints were intracerebral hemorrhage (ICH), symptomatic intracerebral hemorrhage (sICH) and mortality at 3-month. ICH was assessed by CT or magnetic resonance imaging (MRI) scan. sICH was defined according to the ECASS III definition ([@B14]). The primary efficacy outcomes were favorable functional outcome and functional independence which were assessed by trained physicians employing mRS scores at 3 months with telephone questionnaires or clinic visits. A mRS score of 0--1 was considered as favorable functional outcome, a mRS score of 0 to 2 was considered as functional independence, and a mRS score of 6 indicated mortality. Secondary efficacy outcomes included neurological improvement at 24 h, 3 d and discharge. NIHSS scores were evaluated throughout the hospitalization to ascertain neurological improvement. Neurological improvement was defined as a reduction of at least 4 points on the NIHSS score.

Statistical Analysis
--------------------

All categorical variables are summarized as numbers and frequency (%), and chi-squared test or the Fisher exact test was conducted to detect differences between groups. For continuous variables, mean with standard deviation (SD) or median with interquartile range (IQR) are presented to summarize data, and between-group comparisons were performed via independent samples 2-tailed *t*-test or Mann-Whitney *U*-test. Multivariable logistic regression models were performed to further determine the association between tirofiban treatment and post-thrombectomy safety and efficacy outcomes. Results of regression analyses are expressed as odds ratios (ORs) with 95% confidence intervals (CIs). Variables that were considered as clinically relevant or with a potential association in the univariate analysis (*P* \< 0.20) were included in the multivariate logistic regression analysis. Statistical analyses were executed by SPSS 22.0 (IBM Corp, Armonk, NY) with the significance level of *P* \< 0.05.

Results {#s3}
=======

Baseline Characteristics
------------------------

[Table 1](#T1){ref-type="table"} displays the demographic and clinical characteristics according to tirofiban use. In this study, 195 AIS patients who underwent MT were recruited, including 71 receiving tirofiban as a combination therapy and 124 did not. In tirofiban group, the average age at onset was 66.2 ± 15.2 years old, 51 subjects (71.8%) were male, 24 (33.8%) were treated with intravenous rtPA. And the median baseline NIHSS score was 14 (IQR, 9-20), the median onset to groin puncture time was 340 (IQR, 215-505) minutes. Baseline characteristics were not significantly different between groups (*P* \> 0.05 each). Demographic and clinical characteristics of subjects with LAA and CE are also summarized in the [Table 1](#T1){ref-type="table"}. Among these enrolled patients, 95 were diagnosed with LAA, 84 with CE. In each subgroup, the baseline characteristics were overall similar between tirofiban and non-tirofiban groups (*P* \> 0.05 each).

###### 

Patients\' demographic and clinical characteristics.

  **Baseline characteristics**            **All patients (*****n*** **=** **195)**   **Large artery atherosclerosis (*****n*** **=** **95)**   **Cardioembolism (*****n*** **=** **84)**                                                                                           
  --------------------------------------- ------------------------------------------ --------------------------------------------------------- ------------------------------------------- ------------------- ------------------- ------- ------------------- ------------------- -------
  Age, y                                  66.2 ± 15.2                                66.3 ± 13.5                                               0.681                                       61.9 ± 10.0         66.0 ± 10.9         0.281   76.2 ± 11.5         68.5 ± 13.3         0.348
  Males, *n* (%)                          51 (71.8)                                  86 (69.4)                                                 0.716                                       33 (84.6)           38 (67.9)           0.064   15 (53.6)           40 (71.4)           0.105
  Smoking, *n* (%)                        28 (39.4)                                  41 (33.1)                                                 0.371                                       23 (59.0)           22 (39.3)           0.059   4 (14.3)            16 (28.6)           0.147
  Diabetes mellitus, *n* (%)              16 (22.5)                                  23 (18.5)                                                 0.503                                       11 (28.2)           9 (16.1)            0.154   5 (17.9)            12 (21.4)           0.701
  Hypertension, *n* (%)                   48 (67.6)                                  80 (64.5)                                                 0.662                                       28 (71.8)           42 (75.0)           0.727   18 (64.3)           35 (62.5)           0.873
  Hypercholesterolemia, *n* (%)           6 (8.5)                                    9 (7.3)                                                   0.764                                       5 (12.8)            6 (10.7)            0.756   1 (3.6)             2 (3.6)             1.000
  Atrial fibrillation, *n* (%)            21 (29.6)                                  45 (36.3)                                                 0.340                                       0 (0)               2 (3.6)             0.511   21 (75.0)           39 (69.6)           0.608
  Coronary heart disease, *n* (%)         15 (21.1)                                  27 (21.8)                                                 0.916                                       3 (7.7)             8 (14.3)            0.516   12 (42.9)           18 (32.1)           0.334
  Previous TIA/stroke, *n* (%)            2 (2.8)                                    0 (0)                                                     0.131                                       0 (0)               0 (0)               --      2 (7.1)             0 (0)               0.108
  Previous cerebral infarction, *n* (%)   10 (14.1)                                  24 (19.4)                                                 0.351                                       5 (12.8)            11 (19.6)           0.382   4 (14.3)            11 (19.6)           0.546
  Previous cerebral hemorrhage, *n* (%)   3 (4.2)                                    3 (2.4)                                                   0.670                                       2 (5.1)             1 (1.8)             0.566   1 (3.6)             2 (3.6)             1.000
  NIHSS on admission                      14 (9--20)                                 15.5 (11--20)                                             0.559                                       11 (7--20)          14 (10--19)         0.204   19 (13--21)         16 (11--20)         0.198
  Fasting blood glucose, mmol/L           6.54 (5.35--8.23)                          6.30 (5.26--7.84)                                         0.383                                       6.13 (5.32--8.57)   6.29 (5.21--7.30)   0.615   6.75 (5.60--8.47)   5.86 (5.14--7.84)   0.243
  Platelet, 10^9^/L                       188 (157--233)                             181 (143--220)                                            0.227                                       212 (170--248)      197 (162--234)      0.337   165 (115--189)      158 (138--203)      0.582
  PT/INR                                  1.00 (0.93--1.10)                          1.01 (0.94--1.12)                                         0.633                                       0.96 (0.92--1.03)   0.98 (0.90--1.06)   0.768   1.06 (0.99--1.14)   1.04 (0.98--1.16)   0.482
  Intravenous thrombolysis, *n* (%)       24 (33.8)                                  55 (44.4)                                                 0.149                                       13 (33.3)           23 (41.1)           0.444   9 (32.1)            27 (48.2)           0.161
  Onset to groin puncture, min            340 (215--505)                             301 (218--433)                                            0.697                                       357 (235--505)      355 (262--558)      0.401   307 (185--595)      256 (203--336)      0.281
  IVT to groin puncture, min              71 (60--80)                                69 (60--79)                                               0.472                                       72 (62--81)         67 (56--80)         0.414   68 (56--80)         72 (66--79)         0.251
  Onset to recanalization, min            440 (290--602)                             375 (305--540)                                            0.623                                       457 (360--600)      440 (342--688)      0.336   410 (282--670)      327 (266--419)      0.054
  Permanent stenting, *n* (%)             7 (10.0)                                   6 (5.2)                                                   0.211                                       6 (15.4)            4 (7.7)             0.246   1 (3.6)             2 (3.7)             0.976
  Balloon angioplasty, *n* (%)            13 (18.6)                                  22 (19.0)                                                 0.947                                       11 (28.2)           20 (38.5)           0.307   2 (7.1)             1 (1.9)             0.226
  Anterior circulation stroke, *n* (%)    54 (76.1)                                  92 (74.2)                                                 0.773                                       24 (61.5)           33 (58.9)           0.798   27 (96.4)           50 (89.3)           0.416
  ICA                                     19 (26.8)                                  25 (20.2)                                                 0.289                                       10 (25.6)           10 (17.9)           0.360   7 (25.0)            13 (23.2)           0.856
  M1-MCA                                  20 (28.2)                                  39 (31.5)                                                 0.631                                       7 (17.9)            17 (30.4)           0.171   12 (42.9)           17 (30.4)           0.256
  M2-MCA                                  15 (21.1)                                  28 (22.6)                                                 0.814                                       7 (17.9)            6 (10.7)            0.313   8 (28.6)            20 (35.7)           0.513
  Posterior circulation stroke, *n* (%)   17 (23.9)                                  32 (25.8)                                                 0.773                                       15 (38.5)           23 (41.1)           0.798   1 (3.6)             6 (10.7)            0.416
  PCA                                     2 (2.8)                                    5 (4.0)                                                   0.661                                       1 (2.6)             4 (7.1)             0.326   0 (0)               0 (0)               --
  BA                                      10 (14.1)                                  21 (16.9)                                                 0.600                                       9 (23.1)            16 (28.6)           0.550   1 (3.6)             3 (5.4)             0.717
  VA                                      5 (7.0)                                    6 (4.8)                                                   0.521                                       5 (12.8)            3 (5.4)             0.198   0 (0)               3 (5.4)             0.212
  Reperfusion, *n* (%)                    62 (87.3)                                  107 (86.3)                                                0.838                                       36 (92.3)           47 (83.9)           0.227   22 (78.6)           48 (85.7)           0.408
  Stroke etiology                         LAA, *n* (%)                               39 (54.9)                                                 56 (45.2)                                   0.345               --                  --                                              
                                          CE, *n* (%)                                28 (39.4)                                                 56 (45.2)                                                                                                                           
                                          Other, *n* (%)                             4 (5.6)                                                   12 (9.7)                                                                                                                            

*TIA, indicates transient ischemic attack; NIHSS, National Institutes of Health Stroke Scale; PT/INR, prothrombin time and international normalized ratio; IVT, intravenous thrombolysis; ICA, internal carotid artery; M1-MCA, M1 segment of the middle cerebral artery; M2-MCA, M2 segment of the middle cerebral artery; PCA, posterior cerebral artery; BA, basilar artery; VA, vertebral artery; LAA, large artery atherosclerosis; CE, cardioembolism*.

Intracerebral Hemorrhage
------------------------

The results of intracerebral hemorrhage are summarized in [Table 2](#T2){ref-type="table"}. Overall, three patients (4.2%) treated with tirofiban experienced sICH and 14 patients (11.3%) not receiving tirofiban experienced sICH. No significant difference was detected in sICH between two groups (*P* = 0.092). The risk of in-hospital ICH was significantly lower in patients receiving tirofiban (18.3 vs. 33.9%; *P* = 0.020). In LAA and CE patients, the rates of sICH also were not significantly different between patients with and without tirofiban (*P* \> 0.05 each). LAA patients treated with tirofiban were associated with lower risk of in-hospital ICH than patients in control group (10.3 vs. 32.1%; *P* = 0.013), however, such association was not observed in CE patients (32.1 vs. 33.9%; *P* = 0.870).

###### 

Effects of Tirofiban treatment on intracerebral hemorrhage in patients with different ischemic stroke etiology.

                                                                          **Tirofiban**   **Without tirofiban**   ***P* value**   **Adjusted OR (95% CI) and *P* value**
  ----------------------------------------------------------------------- --------------- ----------------------- --------------- ----------------------------------------
  **ALL PATIENTS[^\*^](#TN1){ref-type="table-fn"}**                                                                               
  Sich                                                                    3/71 (4.2)      14/124 (11.3)           0.092           0.374 (0.102--1.374), 0.138
  In-hospital ICH                                                         13/71 (18.3)    42/124 (33.9)           0.020           0.382 (0.180--0.809), 0.012
  **LARGE ARTERY ATHEROSCLEROSIS**[^**\#**^](#TN2){ref-type="table-fn"}                                                           
  sICH                                                                    2/39 (5.1)      6/56 (10.7)             0.464           0.529 (0.093--3.000), 0.472
  In-hospital ICH                                                         4/39 (10.3)     18/56 (32.1)            0.013           0.280 (0.081--0.967), 0.044
  **CARDIOEMBOLISM**[^**\$**^](#TN3){ref-type="table-fn"}                                                                         
  sICH                                                                    1/28 (3.6)      5/56 (8.9)              0.658           0.317 (0.029--3.482), 0.347
  In-hospital ICH                                                         9/28 (32.1)     19/56 (33.9)            0.870           0.692 (0.228--2.099), 0.516

*Adjusted for age, gender, NIHSS on admission, previous TIA/stroke, intravenous thrombolysis*.

*Adjusted for age, gender, NIHSS on admission, smoking, diabetes mellitus*.

*Adjusted for age, gender, NIHSS on admission, smoking, previous TIA/stroke, intravenous thrombolysis*.

*sICH, indicates symptomatic intracerebral hemorrhage; ICH, intracerebral hemorrhage*.

Functional Outcome
------------------

[Figures 1](#F1){ref-type="fig"}--[3](#F3){ref-type="fig"} present the distribution of mRS at 3-month in all stroke patients, LAA patients and CE patients, respectively. The results of functional outcome are presented in [Table 3](#T3){ref-type="table"}. At the 3-month follow-up, favorable functional outcome (mRS 0-1) occurred more frequently in tirofiban group than control group (31.0 vs. 16.9%; *P* = 0.023). However, tirofiban treatment was not associated with functional independence (mRS 0-2) and mortality (mRS = 6) (*P* = 0.060 and 0.076, respectively). In LAA patients, the incidences of achieving favorable functional outcome and functional independence were significantly higher in patients treated with tirofiban than those not receiving it (*P* = 0.006 and 0.013, respectively). In CE patients, all these outcomes mentioned above did not differ significantly between subjects with and without tirofiban (*P* \> 0.05 each).

![Distribution of mRS at 3-month in all stroke patients.](fneur-10-01100-g0001){#F1}

![Distribution of mRS at 3-month in large artery atherosclerosis (LAA) stroke patients.](fneur-10-01100-g0002){#F2}

![Distribution of mRS at 3-month in cardioembolism stroke patients.](fneur-10-01100-g0003){#F3}

###### 

Effects of Tirofiban treatment on functional outcomes in patients with different ischemic stroke etiology.

                                                                          **Tirofiban**   **Without tirofiban**   ***P* value**   **Adjusted OR (95% CI) and *P* value**
  ----------------------------------------------------------------------- --------------- ----------------------- --------------- ----------------------------------------
  **ALL PATIENTS[^\*^](#TN4){ref-type="table-fn"}**                                                                               
  3-mo mRS, 0-1                                                           22/71 (31.0)    21/124 (16.9)           0.023           2.087 (0.902--4.827), 0.086
  3-mo mRS, 0-2                                                           30/71 (42.3)    36/124 (29.0)           0.060           1.862 (0.913--3.800), 0.087
  3-mo mRS, 6                                                             15/71 (21.1)    41/124 (33.1)           0.076           0.538 (0.256--1.133), 0.103
  **LARGE ARTERY ATHEROSCLEROSIS**[^**\#**^](#TN5){ref-type="table-fn"}                                                           
  3-mo mRS, 0-1                                                           18/39 (46.2)    11/56 (19.6)            0.006           3.050 (0.969--9.598), 0.057
  3-mo mRS, 0-2                                                           21/39 (53.8)    16/56 (28.6)            0.013           2.281 (0.813--6.401), 0.117
  3-mo mRS, 6                                                             8/39 (20.5)     20/56 (35.7)            0.110           0.444 (0.145--1.359), 0.155
  **CARDIOEMBOLISM**[^**\$**^](#TN6){ref-type="table-fn"}                                                                         
  3-mo mRS, 0-1                                                           2/28 (7.1)      9/56 (16.1)             0.322           0.719 (0.107--4.807), 0.733
  3-mo mRS, 0-2                                                           7/28 (25.0)     18/56 (32.1)            0.500           0.945 (0.276--3.232), 0.928
  3-mo mRS, 6                                                             6/28 (21.4)     13/56 (23.2)            0.854           0.722 (0.202--2.577), 0.616

*Adjusted for age, gender, NIHSS on admission, previous TIA/stroke, intravenous thrombolysis*.

*Adjusted for age, gender, NIHSS on admission, smoking, diabetes mellitus*.

*Adjusted for age, gender, NIHSS on admission, smoking, previous TIA/stroke, intravenous thrombolysis*.

*mRS indicates modified Rankin Scale*.

Treatment Effects
-----------------

Details of treatment effects are provided in [Table 4](#T4){ref-type="table"}. The rates of neurological improvement at 24 h, 3 d and discharge were not significantly different between patients with and without tirofiban (22.5 vs. 29.8%, 28.2 vs. 37.1% and 59.2 vs. 47.6%, respectively, *P* \> 0.05 each). In LAA patients, our results also proved that the rates of neurological improvement at 24 h, 3 d and discharge were not significantly different between two groups (*P* \> 0.05 each). However, CE patients administrated with tirofiban had a significantly lower likelihood to have neurological improvement at 24 h and 3 d (*P* = 0.001 and 0.005, respectively).

###### 

Effects of Tirofiban treatment on treatment effects in patients with different ischemic stroke etiology.

                                                                          **Tirofiban**   **Without tirofiban**   ***P* value**   **Adjusted OR (95% CI) and *P* value**
  ----------------------------------------------------------------------- --------------- ----------------------- --------------- ----------------------------------------
  **ALL PATIENTS[^\*^](#TN7){ref-type="table-fn"}**                                                                               
  Neurological improvement at 24 h                                        16/71 (22.5)    37/124 (29.8)           0.270           0.682 (0.342--1.364), 0.279
  Neurological improvement at 3d                                          20/71 (28.2)    46/124 (37.1)           0.205           0.674 (0.354--1.283), 0.229
  Neurological improvement at discharge                                   42/71 (59.2)    59/124 (47.6)           0.120           1.467 (0.802--2.684), 0.213
  **LARGE ARTERY ATHEROSCLEROSIS**[^**\#**^](#TN8){ref-type="table-fn"}                                                           
  Neurological improvement at 24 h                                        11/39 (28.2)    10/56 (17.9)            0.232           2.598 (0.850--7.942), 0.094
  Neurological improvement at 3d                                          13/39 (33.3)    14/56 (25.0)            0.376           1.897 (0.696--5.172), 0.211
  Neurological improvement at discharge                                   23/39 (59.0)    23/56 (41.1)            0.086           2.157 (0.869--5.358), 0.098
  **CARDIOEMBOLISM[^\$^](#TN9){ref-type="table-fn"}**                                                                             
  Neurological improvement at 24 h                                        3/28 (10.7)     26/56 (46.4)            0.001           0.185 (0.047--0.726), 0.016
  Neurological improvement at 3d                                          6/28 (21.4)     30/56 (53.6)            0.005           0.268 (0.087--0.825), 0.022
  Neurological improvement at discharge                                   17/28 (60.7)    33/56 (58.9)            0.875           0.990 (0.334--2.931), 0.986

*Adjusted for age, gender, NIHSS on admission, previous TIA/stroke, intravenous thrombolysis*.

*Adjusted for age, gender, NIHSS on admission, smoking, diabetes mellitus*.

*Adjusted for age, gender, NIHSS on admission, smoking, previous TIA/stroke, intravenous thrombolysis*.

Multivariate Regression Analysis
--------------------------------

According to multivariate regression analysis, tirofiban was not increase the risk of sICH and mortality at 3-month (adjusted *P* \> 0.05 each) nor was it associated with neurological improvement at 24 h, 3 d and discharge (adjusted *P* \> 0.05 each). Whereas, we observed that tirofiban tended to improve the rates of favorable functional outcome and functional independence at 3-month (adjusted OR = 2.087, 95% CI 0.902--4.827; adjusted OR = 1.862, 95% CI 0.913--3.800). Intriguingly, a lower risk of in-hospital ICH was noted in tirofiban administrated patients (adjusted OR = 0.382, 95% CI 0.180--0.809). Multivariate regression analysis confirmed the safety of tirofiban in both LAA and CE patients (adjusted *P* \> 0.05 each). In terms of efficacy outcomes, tirofiban exhibited strong potential to improve the odds of favorable outcomes at 3-month in LAA patients (adjusted OR = 3.050, 95% CI 0.969--9.598; adjusted OR = 2.281, 95% CI 0.813--6.401), while CE patients who were treated with tirofiban proved to have lower odds of achieving neurological improvement at 24 h and 3d (adjusted OR = 0.185, 95% CI 0.047--0.726; adjusted OR = 0.268, 95% CI 0.087--0.825).

Discussion {#s4}
==========

High safety of tirofiban administration after MT have been demonstrated in our study. According to multivariate regression analysis, tirofiban was not associated with the risk of sICH and mortality at 3-month. Several previous studies also observed that endovascular treatment (EVT) alone has no absolute superiority over tirofiban combined with EVT in terms of safety ([@B10]--[@B12], [@B15]). Moreover, two recent studies that assessing the safety of abciximab (another approved GP IIb/IIIa inhibitors) combined with EVT concluded that abciximab treatment may be relatively safe ([@B16], [@B17]). Al-Mufti et al. found that abciximab administration after emergent carotid stenting caused no death at 3-month follow-up ([@B16]). And among all 99 patients treated with abciximab that Delgado et al. retrospectively assessed, no sICH was occurred ([@B17]). When compared with abciximab, tirofiban have a lower molecular weight and a shorter half-life, hence, tirofiban can penetrate into the thrombus easily and reduced platelet function can be normalized very shortly after the end of tirofiban administration ([@B18]). If abciximab after EVT was reported to be safe for AIS, then safety concern should not be the reason for withholding tirofiban therapy in EVT for AIS.

However, in the study by Kellert et al. they reported a higher risk of developing fatal ICH in patients receiving tirofiban ([@B9]). Several factors can account for this discrepancy. First, in this present study, tirofiban was administrated intra-arterially, while Kellert et al. treated patients with intravenous tirofiban. According to Kwon et al. intra-arterial use of tirofiban has several advantages compared with intravenous administration ([@B19]). One of the major superiority of intra-arterial tirofiban is due to the direct delivery of a concentrated dose to the target thrombus, effective thrombolysis can be achieved rapidly, and thus reduce possible bleeding events ([@B19]). Second, it is worth noting that patients in Kellert et al\'s study had higher NIHSS score on admission ([@B9]). Kellert et al. stated that median NIHSS score of patients received tirofiban was 18 (13, 35), however, median NIHSS score of patients received tirofiban in our study was 14 (9, 20). At last, 20 different catheters/thrombectomy devices/stent systems were used in the study by Kellert et al. some of which might lead to the excess risk for hemorrhagic complications ([@B9]).

Although tirofiban administration was not associated with neurological improvement, we still detected a strong tendency of tirofiban increasing functional independence rate in multivariate analysis, suggesting combined MT and tirofiban strategy is feasible and potentially efficacious when compared with MT alone. In the present study, functional independence at 3-month was achieved in 42.3% of patients. The reported rates of functional independence in previous RCTs of EVT ranged from 32.6 to 53.0% ([@B20]--[@B24]), which are comparable to our rate. Moreover, in 2017, Zhao et al. conducted a observational study attempted to investigate whether intra-arterial tirofiban was safe and effective in AIS patients undergoing MT with second-generation stent retrievers ([@B10]). They concluded that tirofiban seems to improve the odds of long-term functional independence which was consistent with our results ([@B10]). However, during the intervention, interventionists may be inclined to use tirofiban in patients with high possibility of having unfavorable outcome. As a result, this selection bias may have underestimated the efficacy of tirofiban.

Effects of tirofiban may depend on AIS etiology. In this study, we found that in patients with LAA stroke, tirofiban seems to lead to higher odds of neurological improvement at 24 h and favorable functional outcome at 3-month. By contrast, stroke patients of CE etiology who treated with tirofiban had significantly lower odds of neurological improvement (at 24 h and at 3d) and tended to have unfavorable outcomes at 3-month. Our findings may be attributed to the actual structure of thrombi. It is known that CE-induced occlusion are rich in red cells and are considered as red thrombi, whereas LAA-induced occlusion consist mainly of platelets which are referred to as white thrombi ([@B13]). Thus, tirofiban, as a non-peptide, short-acting GP IIb/IIIa antagonist which can prevent platelet aggregation, is beneficial to LAA patients by maintaining the reperfusion. Besides, in patients with occlusion related to intracranial atherosclerosis, tirofiban can stabilize the inflamed stenotic lesion and maintain blood flow which is helpful in preventing some ischemic events caused by inflammatory and platelet aggregation ([@B25]). Due to these aforementioned reasons, it may not be surprising that tirofiban is more effective in LAA patients. Moreover, atherosclerotic occlusion may be more difficult to achieve reperfusion with MT and reocclusion can frequently occur even after successful recanalization ([@B8]), so tirofiban as an adjuvant rescue strategy may be required. Therefore, tirofiban should be recommended to ischemic patients of LAA etiology, while tirofiban may not be suitable for CE patients because of the lack of efficacy. However, whether tirofiban treatment can adversely affect efficacy outcomes of CE patients treated with MT would be of interest as future research.

Certain limitations of our study need to be acknowledged. First, due to the relatively small number of patients treated with tirofiban enrolled in this observational study, high level evidence cannot be established. Further RCTs with a larger sample size are needed to have conclusive data for clinical practice. Second, the use of tirofiban or not was up to the neurointerventional specialists\' discretion according to patient conditions during the procedure, which in turn leaves room for bias. Third, our study took an extraordinary effort to focus on patients with LAA and CE, as a result, other stroke etiologies of SVO, OD, UD as described in TOAST were overlooked. Last but not least, some parameters were missed. Perioperative managements may affect the risk of sICH and mRS scores at 3-month. However, these important baseline characteristics were not assessed in this present study. The influence of perioperative managements on post-thrombectomy outcomes may potentially exist.

Conclusions {#s5}
===========

In LAA stroke patients, tirofiban combined with MT appears to be safe and potentially effective. By contrast, in CE stroke patients who underwent MT, tirofiban may not lead to better clinical outcomes. However, large RCTs are needed to further clarify our observation.

Data Availability Statement {#s6}
===========================

All datasets generated for this study are included in the manuscript/[Supplementary Files](#s10){ref-type="sec"}.

Ethics Statement {#s7}
================

The studies involving human participants were reviewed and approved by The ethics committee of Nanjing First Hospital, Changsha Central Hospital and People\'s Hospital of Hunan Province. The patients/participants provided their written informed consent to participate in this study.

Author Contributions {#s8}
====================

CS and XiL collected and analyzed the data, drafted and made critical revisions to the manuscript. ZheZ analyzed the data and performed all statistical analyses, and made critical revisions to the manuscript. XC, CH, XuL, YS, YZ, YL, MI, LN, BS, FW, XZ, JH, and ZhiZ treated the patients and collected the data, and made critical revisions to the manuscript. JZh and JZo conceived the study, treated the patients, collected and analyzed the data, drafted and made critical revisions to the manuscript.

Conflict of Interest
--------------------

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Funding.** This study was supported by National Natural Science Foundation of China grant 81673511, Jiangsu key Research and Development Plan grant BE2017613, Jiangsu Six Talent Peaks Project grant WSN-151, and Nanjing Medical Science and Technique Development Foundation grant QRX17020 and ZKX15027.

Supplementary Material {#s10}
======================

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fneur.2019.01100/full#supplementary-material>

###### 

Click here for additional data file.

[^1]: Edited by: Diogo C. Haussen, Emory University, United States

[^2]: Reviewed by: Alhamza Al-Bayati, Emory University, United States; Alicia C. Castonguay, University of Toledo, United States

[^3]: This article was submitted to Endovascular and Interventional Neurology, a section of the journal Frontiers in Neurology

[^4]: †These authors have contributed equally to this work
